Evidence map›Paper›PMID 40506875›Full record

ReviewDiagnostics (Basel, Switzerland)2025

Diagnostic Methods and Biomarkers in Inflammatory Bowel Disease.

Andrew M Kaz, Nanda Venu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. The Emerging Role of Ultrasonography in Ulcerative Colitis.Diagnostics (Basel, Switzerland) · 2026
    Review
  3. Article
  4. Review
  5. Alleviating Effects ofInternational journal of molecular sciences · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Andrew M KazGI Section, Hospital and Specialty Medicine, VA Puget Sound Health Care System, Seattle, WA 98108, USA.ORCID 0000-0003-4366-351X
Nanda VenuDepartment of Medicine/Gastroenterology, University of Washington School of Medicine, Seattle, WA 98195, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) refers to a chronic inflammatory condition involving the GI tract that includes Crohn's disease (CD) and ulcerative colitis (UC). These conditions are believed to arise in genetically predisposed individuals who develop an exaggerated immune response to the intestinal microbiota. A timely and accurate diagnosis of IBD is essential because diagnostic delays can result in intestinal damage that is irreversible, leading in some cases to intestinal dysfunction and the need for surgery. Diagnostic delays are common in cases when GI symptoms are mild and nonspecific. When IBD is suspected, the common diagnostic algorithm includes laboratory analyses, cross-sectional radiologic imaging, and endoscopy with biopsy and histological analysis. Other diagnostic biomarkers, including those found in the serum, stool, and urine, have also been evaluated in IBD. Newer artificial intelligence (AI)-based technologies are now being developed, and these will likely play an important future role in the diagnosis and management of IBD.

Indexed as

artificial intelligencebiomarkerCrohn’s diseasediagnosisendoscopyinflammatory bowel diseaseintestinal ultrasoundulcerative colitisvideo capsule endoscopy

Identifiers

PMID40506875
PMCPMC12154505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.